Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Allogene Therapeutics, Inc. (ALLO) had Operating Cash Flow per Share of $-0.42 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-50.94M |
|
-- |
|
-- |
|
$56.82M |
|
$-56.82M |
|
$5.88M |
|
$-50.94M |
|
$-50.94M |
|
$-50.94M |
|
$-50.94M |
|
$-50.94M |
|
$-50.94M |
|
$-56.82M |
|
$-54.88M |
|
218.93M |
|
218.93M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$282.65M |
|
$78.86M |
|
$187.94M |
|
$470.59M |
|
$31.68M |
|
-- |
|
$94.36M |
|
$126.03M |
|
$344.56M |
|
$344.56M |
|
$344.56M |
|
220.13M |
|
| Cash Flow Statement Financials | |
$-91.96M |
|
$50.01M |
|
$19.06M |
|
$85.51M |
|
$62.62M |
|
$-22.89M |
|
$20.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-92.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.78% |
|
-14.78% |
|
-10.83% |
|
-14.78% |
|
$1.57 |
|
$-0.42 |
|
|
Operating Cash Flow per Share |
$-0.42 |